Home

EDV
EDV
Covid EDV Vax Booster_Immune_compromised
COVID-19 Vaccine Trial for Immune-Compromised People

We are looking for volunteers who:
• are 18 years and older
• are immune-compromised/suppressed
• have been vaccinated or recovered from COVID-19 at least 3 months prior

For more information, please contact our Clinical Trials Team

For more information
MORE INFO
EDVs
The EDV nanocell is a first-in-class cyto-immunotherapy platform targeting the tumor directly and leveraging the patient’s own immune system.
previous arrowprevious arrow
next arrownext arrow
Shadow

 

Breaking News

EnGeneIC has won the 2022 Australian Financial Review BOSS Prestigious Award for the most Innovative company in Healthcare (Australia and New Zealand)


The Awards ceremony was held at the Fullerton Hotel (Sydney). You can see the story in the AFR print version or here:
Vaccine for COVID mutants steals the limelight for health innovation (afr.com)


 

EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response

Click for full story

Works against mutant strains including Delta & Omicron. No need for refrigeration during transport and storage. No added stabilisers or chemicals. Safety and immune response clinical trial recruiting now in Melbourne, Sydney & Perth to follow. Efficacy trial planned for USA.

For more information about becoming a volunteer for the COVID-19 EDV™ Vaccine Trial contact our Clinical Trials Team.

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology